Dr. Gilad noted that Atrin planned to file an IND for its lead ATR-inhibitor during 2017, with the goal of initiating human testing of that potential cancer drug in 2018.
Dr. Sperl was most recently the Senior Director, Manufacturing, for MediVector, Inc. and was an independent industry consultant on CMC matters for a variety of companies. His corporate career has included CMC-related Vice Presidencies at Logical Therapeutics, Cetek, and Point Therapeutics. Prior to that he was Director of Preclinical Development at ArQule, Inc., and before that, held a series of increasingly responsible chemistry positions at Cell Pathways, Inc.
About Atrin Pharmaceuticals
Atrin Pharmaceuticals is a privately held biopharmaceutical company, based in Doylestown, PA, that aims to change the way cancer is being treated. The company is engaged in the discovery and development of innovative treatments for cancer. Atrin's most advanced program is focused on a new class of compounds that are highly specific inhibitors of ATR, a key mediator of DNA repair. Atrin is further assembling a pipeline of additional drug candidates, identified via the company's proprietary, human cell-based, high-throughput screening platform, Atrize™. Applicable to both drug discovery/development and the evaluation of patient-specific treatments, Atrize enables the rapid identification and evaluation of compounds that are effective in inhibiting cancer cell viability without adversely affecting healthy cells. For more information on the company, please visit our website at http://atrinpharma.com/.
Logo - http://photos.prnewswire.com/prnh/20161018/429918LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/atrin-pharmaceuticals-appoints-gerhard-j-sperl-phd-as-vice-president-chemistry-manufacturing-and-controls-300349512.html
SOURCE Atrin Pharmaceuticals